• The event was an investor webinar titled "Granules India 2.0 Comprehensive Transformation Underway" hosted by IIFL Capital Services Limited.
  • The webinar was held on September 29, 2026 (as referenced in the submission letter dated September 26, 2026). The specific time and time zone were not disclosed in the transcript.
  • The stated purpose was to understand the company's key growth engines and comprehensive transformation strategy with the promoters and senior management team.
  • The meeting included opening commentary from management followed by a Q&A session. It was a strategic update presentation, not specifically tied to an earnings announcement.
  • Management participants included:
  • Dr. Krishna Prasad Chigurupati, Chairman and Managing Director
  • Ms. Priyanka Chigurupati, Executive Director
  • Mr. Vijay Ramanavarapu, President, Granules Pharmaceuticals, Inc.
  • Mr. Sanjay Kumar, CEO, Senn Tides India Private Limited
  • Mr. Mukesh Surana, CFO, Granules India Limited
  • The transcript was made available pursuant to Regulation 46 of the SEBI (LODR) Regulations, 2015, via submission to the stock exchanges. No mention was made of presentation decks, recordings, or other materials being hosted elsewhere.
  • The company did not include specific compliance language regarding unpublished price sensitive information (UPSI) in this transcript.

Financial Highlights & Strategic Updates

  • The discussion focused on Q1 FY27 and full-year FY26 performance context, though specific quarterly results were not detailed.
  • Financial Performance: Gross margin expanded by ~15 percentage points over four years to 65% in FY26. EBITDA margin improved by 3 percentage points to 22%. R&D investment increased from ~3% of revenue a few years ago to 6% in Q1 FY27. ROCE improved by ~1 percentage point YoY to 18%. Cash flow from operations averaged ~73% of EBITDA over the last four years.
  • Growth Strategy: The company outlined four growth engines:

1. Controlled Substances: Granules is now the 3rd largest controlled substance manufacturer in the US by value (was 8th in July 2025). Focus on Schedule II ADHD drugs (Methylphenidate, Dexmethylphenidate, Amphetamines, Lisdexamfetamine) with 8 products approved, 7 marketed. DEA quota has increased annually.

2. Complex Generics & Early Market Opportunities: Complex generics contribution increased from 1% of revenue in FY20 to 33% in FY26 (~45-50% of finished dosages). Two sole first-to-file ANDAs filed (Generic Lumryz and Generic Dyanavel) with combined US market size >$350M. Another potential sole FDF filed in oncology. Pipeline of 4-5 additional first-to-files targeting commercialization between FY30-34.

3. Oncology: Shifting strategy to selected molecules with technical complexity and early market entry. Two ANDAs filed currently, with ~6 more planned for filing in the current year and early next year. First product expected to launch in FY29.

4. Peptide CDMO: Acquired Senn Chemicals (Switzerland). Targeting $50M annual revenue run rate in 3 years and $100M in 5 years. Immediate priority is profitability in FY27. Also evaluating oligonucleotide and ADC-related capabilities.

  • Capital Allocation: ₹2,000 crore planned organic capital expenditure over next 3-4 years across complex generics, oncology, peptide CDMO, US operations, and digitalization/AI initiatives. Company is in a consolidated net cash position post-preferential warrant exercise in September 2026.
  • Geographic Strategy: US remains anchor market (75% of revenue). Expanding to specialty/institutional segments (first launch in FY29) and launching B2C division in Canada next year. Building API and PFI-led presence in Europe and ROW markets, targeting meaningful presence in Latin America and other international markets by FY30.

Additional Notes Section

  • The document is the transcript of the webinar submitted to the exchanges in compliance with SEBI regulations.
  • No financial attachments (invites, decks, etc.) were included with this transcript submission.
  • The transcript contained extensive strategic and financial information presented during the webinar, including specific financial metrics, growth targets, and pipeline details.